OMCL logo

Omnicell Stock Price

Symbol: NasdaqGS:OMCLMarket Cap: US$1.5bCategory: Healthcare

OMCL Share Price Performance

US$33.09
-12.34 (-27.16%)
24.8% undervalued intrinsic discount
US$44.00
Fair Value
US$33.09
-12.34 (-27.16%)
24.8% undervalued intrinsic discount
US$44.00
Fair Value
Price US$33.09
AnalystConsensusTarget US$44.00

OMCL Community Narratives

AnalystConsensusTarget·Updated
Fair Value US$44.00 24.8% undervalued intrinsic discount

OmniSphere Adoption Will Simplify Healthcare Medication Management

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative

Recent OMCL News & Updates

Omnicell (NASDAQ:OMCL) May Have Issues Allocating Its Capital

Jul 16
Omnicell (NASDAQ:OMCL) May Have Issues Allocating Its Capital

Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 27% Below Their Intrinsic Value Estimate

Jun 28
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 27% Below Their Intrinsic Value Estimate
User avatar

Near-shoring And Digitization Will Drive Stability Despite Tariff Challenges

Supply chain improvements and near-shoring are expected to offset cost pressures, while a shift to recurring SaaS and services enhances earnings stability and valuation potential.

Omnicell, Inc. Key Details

US$1.1b

Revenue

US$645.1m

Cost of Revenue

US$504.5m

Gross Profit

US$481.4m

Other Expenses

US$23.1m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
0.50
Gross Margin
43.88%
Net Profit Margin
2.01%
Debt/Equity Ratio
27.0%

Omnicell, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet with questionable track record.

0 Risks
3 Rewards

About OMCL

Founded
1992
Employees
3650
CEO
Randall Lipps
WebsiteView website
www.omnicell.com

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Market Insight

Market sentiment on BTC treasury companies is moving, and with volatility rising, disagreements over their future prospects are as heated as ever.
Continue reading

U.S. Market Performance

  • 7 Days: 0.2%
  • 3 Months: 9.3%
  • 1 Year: 15.5%
  • Year to Date: 9.5%
Over the last 7 days, the market has remained flat, although notably the Energy sector gained 3.9% in that time. As for the longer term, the market has risen 15% in the past 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›